BioSig Technologies Inc (OQ:BSGM)

Business Focus: Advanced Medical Equipment & Technology

Apr 04, 2024 11:35 am ET
BioSig Engages Consulting Firm for Business Model Strategies
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that it appointed Bridge Associates...
Feb 20, 2024 10:00 am ET
BioSig Announces Reduction of its Workforce
-- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.  About...
Feb 06, 2024 08:30 am ET
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that physicians have completed...
Jan 31, 2024 11:15 am ET
BioSig Announces Reverse Stock Split
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it intends to effect a...
Jan 30, 2024 08:30 am ET
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended...
Dec 06, 2023 02:20 pm ET
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent...
Nov 13, 2023 04:30 pm ET
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously...
Nov 09, 2023 08:00 am ET
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that...
Nov 07, 2023 08:00 am ET
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization,...
Nov 02, 2023 08:00 am ET
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that Mayo Clinic-Phoenix—an...
Nov 01, 2023 08:30 am ET
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that the U.S. Patent and Trademark...
Aug 24, 2023 10:30 am ET
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization,  today is providing an update since the launch of BioSig’s...
Aug 23, 2023 08:30 am ET
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today a subscription model for its PURE EP™ Platform....
Aug 22, 2023 08:00 am ET
BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today the release of new software features for the...
Jul 25, 2023 08:30 am ET
BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the completion of a seed funding round raising...
Jul 20, 2023 09:31 am ET
Thinking about buying stock in ZIM Integrated Shipping, Telus Corp, Rivian Automotive, Greenidge Generation Holdings, or BioSig Technologies?
NEW YORK, July 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZIM, TU, RIVN, GREE, and BSGM.
Jul 20, 2023 07:11 am ET
BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that its subsidiary BioSig AI Sciences, Inc....
Jun 29, 2023 08:30 am ET
BioSig Joins Webull Corporate Connect
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is now actively participating on the...
Jun 27, 2023 08:30 am ET
BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and...
May 25, 2023 09:00 am ET
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform's precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation. All three studies showed significant improvements over the conventional methods use
May 19, 2023 07:30 am ET
New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias
Researchers from Cleveland Clinic will be presenting data from three abstracts at Heart Rhythm 2023 that evaluated an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI)—a type of ablation procedure used to treat atrial...
May 03, 2023 09:00 am ET
BioSig to Highlight New Data from the PURE EP™ Platform at Heart Rhythm 2023
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it will be presenting data at Heart Rhythm...
Mar 27, 2023 08:38 am ET
BioSig Announces New Advisory Board Member Edwin Wang
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Mar 24, 2023 08:30 am ET
BioSig Announces New Advisory Board Member Lorraine Spurge
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Mar 13, 2023 07:30 am ET
BioSig Confirms No Exposure to Silicon Valley Bank
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Feb 22, 2023 07:30 am ET
BioSig Regains Compliance With All Nasdaq Listing Standards
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Feb 17, 2023 07:36 am ET
Thinking about buying stock in iBio, Jasper Therapeutics, BioSig Technologies, DraftKings, or Eos Energy?
NEW YORK, Feb. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, JSPR, BSGM, DKNG, and EOSE.
Feb 17, 2023 07:30 am ET
BioSig Awarded US Patent Claims for its Universal Notch Filter Technology
Patent can remove any fixed frequency interfering with original signal of interest preserving critical intracardiac dataBioSig now has 56 worldwide fundamental granted/allowed patents in the field of digital signal processing BioSig...
Feb 07, 2023 08:00 am ET
BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly brings 15 years of public company CFO experience, including 9 years of leadership with RF chip technology giant Qorvo BioSig...
Jan 19, 2023 08:30 am ET
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The Company has built a robust pipeline of commercial sale prospects and expects multiple closings in first...
Jan 10, 2023 08:30 am ET
BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology
Leading Midwest healthcare system reports significant cost savings and noise reduction following evaluation of the PURE EP™ System Medical center signs agreement to acquire the Company’s digital signal processing technology for arrhythmia care...
Dec 14, 2022 04:30 pm ET
Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Dec 14, 2022 08:00 am ET
BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Dec 06, 2022 08:30 am ET
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System,...
Oct 24, 2022 11:03 am ET
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology Clinical investigations conducted by Cleveland Clinic could expand...
Oct 12, 2022 10:00 am ET
BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System,...
Oct 07, 2022 09:35 am ET
BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System,...
Sep 22, 2022 09:00 am ET
BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™...
Sep 16, 2022 09:30 am ET
Taglich Brothers Initiates Coverage of BioSig Technologies, Inc.
Taglich Brothers, Inc. announces it has initiated coverage of BioSig Technologies, Inc. (NASDAQ: BSGM). BioSig Technologies, Inc., headquartered in Westport CT, is a medical technology company that is in the early stages of commercializing an...
Aug 30, 2022 09:37 am ET
BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth
Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage BioSig...
Aug 25, 2022 09:34 am ET
Thinking about buying stock in Alaunos Therapeutics, BioSig Technologies, Futu Holdings, Hall of Fame Resort & Entertainment, or Verve Therapeutics?
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TCRT, BSGM, FUTU, HOFV, and VERV.
Aug 24, 2022 09:17 am ET
BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence
Leading Medical Center of Excellence adds second PURE EP™ System for evaluation, broadening physician access to the Company’s signal processing technology PURE EP™ is now being evaluated at both Main and Fairview campuses of Cleveland Clinic’s...
Aug 17, 2022 09:15 am ET
BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
Aug 16, 2022 09:47 am ET
BioSig Sees Positive Momentum from Sales Pipeline Growth
Company sees increase in medical centers entering into 60-day evaluation agreements Existing customers seeing positive results from PURE EP™ System expected to increase number of units purchased BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig"...
Jul 21, 2022 10:00 am ET
BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
Jul 07, 2022 08:30 am ET
BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center
OPRMC marks our first leasing agreement under new program Company also inks national master agreement with one of the largest U.S. healthcare systems BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical...
Jun 29, 2022 05:45 pm ET
BioSig Announces Closing of Public Offering of Common Stock
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
Jun 24, 2022 09:30 am ET
BioSig Announces Pricing of Public Offering of Common Stock
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
Jun 23, 2022 04:26 pm ET
BioSig Announces Proposed Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jun 22, 2022 08:00 am ET
BioSig Announces New Evaluation Agreement for its PURE EP System with Cleveland Clinic
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
May 26, 2022 10:50 am ET
Thinking about buying stock in LianBio, BioSig Technologies, Nordstrom, Apyx Medical, or Bloomin' Brands?
NEW YORK, May 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LIAN, BSGM, JWN, APYX, and BLMN.
May 26, 2022 09:08 am ET
BioSig Advances its PURE™ System Commercial Launch to Medical Centers Nationwide
Commercial pipeline to include 30 advanced leads at Medical Centers of Excellence Company’s development and operational infrastructure will be on track to support anticipated sales growth following commercial rollout on July 1, 2022...
May 25, 2022 09:47 am ET
BioSig’s PURE EP™ System to be Featured During EPLive 2022
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
May 11, 2022 08:30 am ET
BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements
To date, Company's FDA 510(k) cleared PURE EP(TM) system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States The Company adds new executives to accelerate sustained commercial momentum...
Apr 19, 2022 09:10 am ET
BioSig to Present at Heart Rhythm 2022
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today...
Apr 07, 2022 08:30 am ET
BioSig to Present at NobleCon18 Capital Markets Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 29, 2022 10:06 am ET
BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 23, 2022 08:00 am ET
BioSig Announces Closing of Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Mar 22, 2022 08:00 am ET
BioSig Technologies, Inc. Announces $3 Million Financing with Family Office
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 16, 2022 09:00 am ET
BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jan 26, 2022 01:00 pm ET
BioSig Awarded US Patent Claims for its PURE EP™ Noise-Filtering Technology
Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technologyThe Company now has 49 issued or allowed worldwide patents covering its novel technology for arrhythmia care...
Jan 07, 2022 10:20 am ET
BioSig to Present at the 27th Annual International AF Symposium
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jan 06, 2022 08:30 am ET
BioSig to Present at the 24th Annual Virtual Needham Growth Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 21, 2021 09:00 am ET
BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 16, 2021 09:15 am ET
BioSig Expands Its Clinical Footprint In Florida
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 13, 2021 08:30 am ET
BioSig to Host Conference Call on December 21, 2021
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 06, 2021 10:00 am ET
BioSig to Participate in the Benzinga All Access Event on December 14, 2021
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 01, 2021 09:25 am ET
BioSig Technologies, Inc. Appoints Gray Fleming as Chief Commercial Officer
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 17, 2021 09:45 am ET
BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 16, 2021 09:52 am ET
BioSig Initiates Artificial Intelligence Development Program with Technion – Israel Institute of Technology
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Nov 11, 2021 02:45 pm ET
BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For Arrhythmia Care
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 10, 2021 09:20 am ET
BioSig Adds To Its Clinical Footprint In Texas
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 08, 2021 11:30 am ET
BioSig Installs its Signal Processing Technology for Arrhythmia Care at a Leading Hospital in Boston
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 04, 2021 11:00 am ET
BioSig Expands its Installation Base in Texas
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 01, 2021 12:30 pm ET
BioSig Increases Case Volume Estimates
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Oct 12, 2021 09:15 am ET
BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Oct 04, 2021 08:30 am ET
Clinical Data Acquired by the PURE EP™ System Published in the Journal of Cardiac Electrophysiology
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Sep 28, 2021 09:15 am ET
BioSig Selects Plexus Corp. as its Manufacturing Partner
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Sep 21, 2021 10:30 am ET
BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Sep 13, 2021 08:00 am ET
BioSig Increases Installation Footprint Adding St. Elizabeth’s Medical Center to Roster of Premium Medical Institutions Utilizing the PURE EP System
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Aug 31, 2021 10:00 am ET
BioSig Confirmed as a Participant of The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Virtual Symposium
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Aug 19, 2021 11:00 am ET
BioSig’s Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 20, 2021 02:00 pm ET
BioSig To Host Presentations from Physician Users of its Signal Processing System for Arrhythmia Care during the annual Heart Rhythm 2021 convention
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 13, 2021 02:30 pm ET
BioSig Latest Installation Broadens Clinical Footprint for its Signal Processing Technology for Electrophysiology
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jul 12, 2021 10:30 am ET
BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care
Company to present results from PURE EP 2.0 Study - a multi-center, blinded, and randomized clinical trialLeading physicians evaluated signal data recorded during 51 cardiac ablation procedures across three medical centers of excellence BioSig...
Jul 07, 2021 04:10 pm ET
BioSig Announces Closing of Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 07, 2021 09:36 am ET
BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jul 02, 2021 08:15 am ET
BioSig Announces Pricing of Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 01, 2021 04:05 pm ET
BioSig Announces Proposed Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jun 30, 2021 09:35 am ET
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
The Company recently increased its procedural volume targets due to accelerated technology usageBioSig expands its commercial team to target technology adoption across three strategic regions BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig”...
Jun 28, 2021 09:45 am ET
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jun 22, 2021 10:06 am ET
BioSig’s Signal Processing System for Electrophysiology Featured in Two Clinical and Scientific Presentations during the annual Heart Rhythm 2021 convention
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jun 15, 2021 08:30 am ET
BioSig Technologies, Inc. to Present New Clinical Data at Heart Rhythm 2021 Annual Convention
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jun 07, 2021 08:30 am ET
BioSig Technologies, Inc. to Present at the LD Micro Invitational XI Virtual Event
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
May 28, 2021 10:30 am ET
BioSig Technologies, Inc. to Present at the Jefferies Virtual Healthcare Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
May 21, 2021 09:15 am ET
BioSig Technologies, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
May 04, 2021 09:15 am ET
BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing System
The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021 44 physicians have conducted over 800 arrhythmia patient cases to date Currently conducting patient cases in 9...
May 03, 2021 12:00 pm ET
BioSig Technologies, Inc. Invited to Present at Wall Street Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Apr 27, 2021 09:30 am ET
BioSig’s PURE EP(tm) System Evaluated with Patients at Mayo Clinic in Arizona
The clinic is conducting an evaluation of the PURE EP(tm) System, a signal processing technology for cardiac arrhythmia treatmentsNew installation follows Mayo Clinic in Florida that has been conducting patient cases with the technology since...
Apr 15, 2021 11:45 am ET
BioSig Expands Commercial Team in Two Strategic Regions
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Apr 14, 2021 09:29 am ET
BioSig Launches Enhanced Signal Processing Capabilities for Advanced Cardiac Signal Analysis Through its Electrophysiology Platform
The latest release represents the most advanced software version of the PURE EPTM System, signal processing technology for treatments of irregular heartbeats BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical...
Apr 13, 2021 09:32 am ET
BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study
51 patients undergoing elective cardiac ablation treatments were enrolled in the trial at Mayo Clinic, Massachusetts General Hospital, and St. David’s Medical CenterThe trial is designed to demonstrate the quality and clinical value of the PURE...
Apr 09, 2021 09:32 am ET
BioSig Invited to Join Alliance for Artificial Intelligence in Healthcare (AAIH)
Global leaders, including Amazon, Bayer, and GE Healthcare, joined the AAIH to date to collaborate on developing novel solutions to improve the quality of care and reduce failure ratesThe Company recently launched a new AI program with the Mayo...
Apr 08, 2021 09:32 am ET
EP Lab Digest Features Physician Experience with BioSig’s Cardiac Signal Acquisition Technology
Leading industry publication highlights the rising importance of intracardiac signals in complex cardiac ablations that treat irregular heart rhythm disordersHigh-quality intracardiac signals are deemed essential to determine ablation endpointsPURE...
Apr 06, 2021 09:45 am ET
BioSig lands Commercial Sales to Leading Hospital System
World class healthcare institution adopts PURE EP™  across multiple StatesMedical centers resuming elective procedures helps drive sales acceleration BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology...
Apr 05, 2021 10:00 am ET
BioSig Technologies, Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 30, 2021 08:30 am ET
BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology
Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technology designed to elevate treatments for cardiac arrhythmias Atrial fibrillation is the most common arrhythmia type,...
Mar 29, 2021 09:15 am ET
BioSig Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
Company expands clinical footprint, installations and commercial sales with leading hospitalsNeurostimulation division to develop a novel sensing and stimulation technology to optimize neurostimulation therapies and develop novel solutions to...
Mar 19, 2021 12:15 pm ET
BioSig CEO Kenneth L. Londoner to Present at the Benzinga Biotech Small Cap Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 10, 2021 05:30 pm ET
BioSig CEO Kenneth L. Londoner to Present at the Oppenheimer 31st Annual Healthcare Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 09, 2021 04:45 pm ET
BioSig CEO Kenneth L. Londoner to Present at the 33rd Annual Virtual ROTH Conference
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Mar 04, 2021 09:15 am ET
BioSig Awarded U.S. Patent Claims for its NeuroClear™ Subsidiary
The patent is exclusively licensed from Mayo Foundation for Medical Education and Research Claims address methods and materials for improving the treatment of hypertensionFifteen additional licensed worldwide patent applications are pending,...
Feb 16, 2021 08:45 am ET
BioSig Appoints Brenda Castrodad to Lead Human Resources
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Feb 11, 2021 07:30 am ET
Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027
Palm Beach, Fl., Feb. 11, 2021 /PRNewswire/ -- Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart diseases and other heart-related problems.  These devices play essential role prevention and treatment of cardiovascular diseases. The cardiovascular devices include implantable cardioverter defibrillators, implanted heart rhythm monitors, pacemakers, and various other devices. The cardiovascular devices market is currently witnessing considerable demand across the globe. Increasing awareness about the various cardiovascular diseases and increasing ger
Feb 10, 2021 10:00 am ET
Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Feb 08, 2021 07:35 am ET
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Feb 08, 2021 07:35 am ET
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.
Feb 02, 2021 08:00 am ET
BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System
Global market for AI in healthcare is estimated to reach $45.2 billion by 2026 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed...
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jan 28, 2021 07:35 am ET
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, February 4th  with the first live webcast at 9:00 AM ET.
Jan 27, 2021 04:30 pm ET
BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase
Company to provide corporate overview and progress on the rollout of the PURE EP™ System BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform...
Jan 15, 2021 09:32 am ET
BioSig to Present at the 26th Annual International AF Symposium
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jan 14, 2021 09:32 am ET
BioSig PURE EP System Featured in the Editorial of EP Lab Digest
Leading industry publication calls attention to ongoing challenges in the electrophysiology labPURE EP System is highlighted as a novel technological solution BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical...
Jan 13, 2021 09:32 am ET
BioSig Deploys Vuzix M400 Smart Glasses to Offer Remote Servicing Capabilities in Compliance with COVID-19 Travel Restrictions
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jan 13, 2021 07:00 am ET
Sidoti Virtual Investor Conference
Presentation Times and Weblinks Released for Over 60 Presenting Companies
Jan 12, 2021 09:32 am ET
BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jan 06, 2021 10:00 am ET
BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Dec 18, 2020 08:30 am ET
BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Dec 11, 2020 07:30 am ET
BioSig Achieves First Commercial Sale of Three PURE EP Systems
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Dec 10, 2020 03:00 pm ET
BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Dec 03, 2020 11:00 am ET
BioSig to Highlight PURE EP™ System at the Benzinga Global Small Cap Conference
The company's PURE EP™ System is currently installed in six medical centers across the countryEvaluation installations are growing and provide a strong foundation for commercial efforts in 2021 BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig"...
Nov 30, 2020 11:00 am ET
BioSig’s PURE EP System to Support Live Patient Cases during EPLive 2020
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Nov 12, 2020 02:11 pm ET
BioSig to Host Business Update Conference Call on November 18, 2020
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Oct 29, 2020 02:05 pm ET
BioSig Announces Completion of PURE EP™ System Installation at New Medical Center
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Oct 28, 2020 10:00 am ET
BioSig Issues October 2020 Shareholder Update Letter
Company’s PURE EP™ System’s data-driven commercialization is gaining acceptance through new evaluative installations at medical centers of excellenceThe strongest cash balance in its history positions the Company well to execute on its strategic...
Oct 26, 2020 07:30 am ET
ViralClear halts its Phase 2 Hospitalized COVID-19 Trial
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), announced the halting of its signal finding Phase 2 trial, “A Phase 2, Randomized, Double-Blind,...
Sep 30, 2020 09:26 am ET
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19
Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster.ViralClear to...
Sep 22, 2020 10:55 am ET
ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Sup
Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices Added 2 new Principal Investigators for...
Sep 21, 2020 11:01 am ET
Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19
Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Merimepodib in Combination with Remdesivir in Hospitalized Adults with COVID-19 Who Require Non-Invasive Ventilation/High Flow Oxygen Devices or Supplemental OxygenPresentation to...
Sep 15, 2020 10:00 am ET
BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Sep 14, 2020 03:00 pm ET
BioSig Announces Abstract Acceptance to Computing in Cardiology 2020
Novel algorithm can successfully reconstruct ECG lead placementsThe method may improve the automated classification of patient conditions and unlock new applications of clinical value BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the...
Sep 14, 2020 10:29 am ET
Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data
Peer-reviewed, blinded, randomized data recently presented at ESC Congress 2020Commercial market update discussionPresentation to include webcast Westport, CT, September 14, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the...
Sep 09, 2020 12:16 pm ET
ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19
Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Merimepodib in Combination with Remdesivir in Hospitalized Adults with COVID-19 Who Require Non-Invasive Ventilation/High Flow Oxygen Devices or Supplemental Oxygen BioSig...
Sep 02, 2020 10:16 am ET
BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 10:45 am ET
BioSig Technologies to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / BioSig Technologies, Inc. (NASDAQ:BSGM), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will be presenting at the 12th Annual LD 500 Conference on Wednesday, September 2, 2020 at 11:40 AM ET. Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will present virtually to an online audience.
Aug 25, 2020 08:30 am ET
BioSig Technologies to Present at The LD 500 Virtual Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Aug 06, 2020 10:00 am ET
Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board
Expert in Infectious Diseases and Immune OncologyViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary,...
Aug 05, 2020 02:09 pm ET
ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board
Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of FameViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM)...
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 04, 2020 09:25 am ET
BioSig Installs PURE EP(tm) System at Massachusetts General Hospital
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Aug 03, 2020 02:00 pm ET
BioSig Awarded CAGE Code by the Systems for Award Management (SAM)
BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jul 30, 2020 01:00 pm ET
BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020
Update on the PURE EP(tm) System installations and commercial progressUpdate on Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or...
Jul 23, 2020 08:30 am ET
BioSig Technologies to Participate in LD Micro’s Zooming with LD
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 20, 2020 01:50 pm ET
ViralClear Announces Formation of Its Scientific Advisory Board
BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory BoardViralClear Pharmaceuticals is Currently in Phase II Trials with Its Lead Asset Merimepodib in the Fight Against...
Jul 17, 2020 02:42 pm ET
BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jul 16, 2020 05:30 pm ET
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
Amended Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of an unsolicited takeoverProvides a guard against tactics to gain control of the Company without paying stockholders a  price that does not...
Jul 16, 2020 11:00 am ET
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.
Jul 16, 2020 10:30 am ET
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of any proposed takeover Provides a guard against tactics to gain control of the Company without paying stockholders a market premium for that control...
Jul 13, 2020 01:42 pm ET
Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company") and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the enrollment of adult patients for its Phase II trial for merimepodib, a broad-spectrum, orally...
Jul 10, 2020 01:15 pm ET
BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government
BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac...
Jul 08, 2020 01:12 pm ET
ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with Albany Molecular Research Inc., (AMRI), a leading global contract research,...
Jul 01, 2020 09:15 am ET
BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jun 29, 2020 08:18 am ET
BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has closed on the sale of 2,187,500 shares of the Company’s common stock, at a...
Jun 24, 2020 09:20 am ET
BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,187,500 shares of the Company’s...
Jun 22, 2020 02:30 pm ET
ViralClear Partners with Catalent on Potential Treatment for COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has signed an agreement with Catalent, the leading global provider of advanced delivery technologies,...
Jun 17, 2020 07:55 am ET
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has commenced patient enrollment with the dosing of the first patient in its Phase II trial for...
Jun 08, 2020 03:02 pm ET
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candid
Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be conducted with merimepodib and remdesivir in multiple sites nationwide with data expected in the...
Jun 05, 2020 09:10 am ET
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has expanded its patient enrollment centers to include St. David’s South Austin...
Jun 04, 2020 09:25 am ET
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Jun 03, 2020 11:45 am ET
BioSig Technologies Expands Intellectual Property Portfolio
U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals, Inc., covering its orally administered broad-spectrum anti-viral solution for the treatment of...
Jun 01, 2020 10:42 am ET
ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19
Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial will be conducted with merimepodib and remdesivir in multiple sites nationwide with data expected in the...
May 28, 2020 08:40 am ET
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.   Mr. Dougherty brings to ViralClear over 30...
May 20, 2020 10:12 am ET
ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
Funding completed in subsidiary without dilution to BioSig common stockPhase II human trials for merimepodib, a broad-spectrum oral anti-viral treatment of adult hospitalized patients with COVID-19, are planned to commence at three Mayo Clinic...
May 18, 2020 08:32 am ET
FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed
Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task ForceRandomized, double blind,...
May 14, 2020 08:15 am ET
ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19
Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.  Even at low concentrations of both drugs significant reduction in viral production occurs.Article highlights recent...
May 07, 2020 03:17 pm ET
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.   Mr. Schmertzler has been the Chairman of the...
May 07, 2020 09:31 am ET
Thinking about buying stock in GenMark Diagnostics, BioSig Technologies, Norwegian Cruise Line, J C Penney, or Delphi Technologies?
NEW YORK, May 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNMK, BSGM, NCLH, JCP, and DLPH.
May 05, 2020 02:10 pm ET
Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Dennis Purcell to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.   Mr. Purcell brings to ViralClear a wealth of...
May 01, 2020 10:39 am ET
BioSig Resumes Clinical Activities with PURE EP System
Clinical support staff to return to perform elective procedures at Texas Cardiac Arrhythmia Institute as of May 4, 2020Company reconfirms its commitment to commercial installations this year BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or...
Apr 30, 2020 09:20 am ET
ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal
BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was...
Apr 24, 2020 02:30 pm ET
BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it will be hosting an investor briefing to provide an update on the progress of its subsidiary ViralClear Pharmaceuticals, Inc, and recent developments of...
Apr 24, 2020 09:25 am ET
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19
In vitro studies demonstrated decrease of viral production by over 98%Upon approval, clinical trial to be conducted at Mayo Clinic under the leadership of Andrew D. Badley, M.D., Professor and Chair of Department of Molecular Medicine and the...
Apr 23, 2020 09:15 am ET
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing.Article highlights recent work done in laboratory studies of COVID-19 with...
Apr 21, 2020 02:36 pm ET
Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm)  – a broad-spectrum orally administered anti-viral candidate for COVID-19 Upon receipt of FDA approval,...
Apr 21, 2020 10:15 am ET
BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that on April 16, 2020 its subsidiary ViralClear Pharmaceuticals, Inc. submitted an application for Vicromax(tm_ (merimepodib, or MMPD) through the FDA’s...
Apr 17, 2020 02:07 pm ET
BioSig Issues April 2020 Shareholder Update Letter
Information on the progress of our subsidiary ViralClear Pharmaceuticals and Vicromax(tm) – a broad-spectrum orally administered anti-viral candidate for COVID-19 Upon receipt of FDA approval, Phase II clinical trial is planned to be conducted at...
Apr 16, 2020 09:45 am ET
Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax™
Broad Spectrum Antiviral Produced by ViralClear Pharmaceuticals, Inc., a subsidiary of BioSig Technologies, Inc.IND filing with FDA expected in coming weeks with study initiation targeted for May 2020Recently published in-vitro data demonstrated...
Apr 09, 2020 08:22 am ET
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
Vicromax shown to  decrease viral production of Covid -19 coronavirus by over 98%Article highlights recent work done in laboratory studies of Covid -19 with Vicromax(tm) at  the Galveston Lational Laboratory at The University of Texas Medical...
Apr 03, 2020 01:10 pm ET
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
Introduction to ViralClear management and scientific teamStrategy for rapid FDA advancement of Vicromax(tm)Update on BioSig core business developments and commercialization plans BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the...
Mar 31, 2020 08:45 am ET
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it appointed Jerome Zeldis, M.D., Ph.D as Executive Chair...
Mar 25, 2020 07:52 am ET
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that its majority-owned subsidiary NeuroClear Technologies, Inc....
Mar 10, 2020 08:05 am ET
Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Mar 04, 2020 07:52 am ET
BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic Neuromodulation
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Mar 03, 2020 12:20 pm ET
BioSig to Webcast its Presentation at the Cowen and Company’s 40th Annual Health Care Conference
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Feb 26, 2020 08:33 am ET
BioSig to Present at the Cowen & Co. 40th Annual Health Care
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Feb 25, 2020 03:25 pm ET
BioSig Announces Closing of Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Feb 21, 2020 08:45 am ET
BioSig Announces $10 Million Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Feb 20, 2020 04:18 pm ET
BioSig Announces Proposed Public Offering of Common Stock
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Feb 19, 2020 08:33 am ET
BioSig Completes 100th Patient Case with PURE EP(TM) System
Commercialization and install plan ahead of scheduleInstallations at new centers are driving patient enrollments and clinical data collection BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.